Secondary Central Nervous System Lymphoma Registry - Charité
Central Nervous System LymphomaNon-Hodgkin LymphomaThe objective of the observation is to collect and document data on treatment strategies for secondary central nervous system lymphoma (SCNSL) in routine clinical practice, whether obtained in the context of clinical trials or outside of trials. In particular, the following questions will be specified: What therapeutic approaches are being pursued? What is the clinical outcome of the various treatment options? What is the frequency of serious adverse events with each therapeutic approach?
Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to...
LymphomaMalignantObservation of a cohort of 400 patients with different types of lymphomas.
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin...
Cardiovascular DisorderClonal Hematopoiesis1 moreThis study assesses how blood cell growth patterns (clonal hematopoiesis), relates to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.
A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen...
Acute Lymphoblastic Leukemiain Relapse5 moreThis is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).
Genotype-guided Treatment in PTCL
Peripheral T Cell LymphomaA multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-X2) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with peripheral T-cell lymphoma.
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Autoimmune Hemolytic AnemiaChronic Lymphocytic Leukemia2 moreThis is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell...
Extranodal NK/T-cell LymphomaThe purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.
Frontline of ASCT in High-risk DLBCL
Diffuse Large B Cell LymphomaThe role of frontline therapy of autologous stem cell transplant (ASCT) in diffuse large B-cell lymphoma (DLBCL) is controversial. The investigators aim to conduct this prospective study to observe the efficacy and safety of ASCT as frontline therapy in DLBCL patients with high-risk disease, defined by an International Prognostic Index (IPI) score equal to or greater than three.
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell...
Refractory or Relapsed B Cell LymphomaThis is a phase 1/2, open-label study to assess the efficacy, safety and pharmacokinetics of ThisCART19A (Allogeneic Anti CD19 CAR-T) in patients with refractory or relapsed CD19 positive B cell Lymphoma.
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Relapsed or Refractory B Cell Non-Hodgkin LymphomaThe goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: can a safe dose of JNJ-90009530 be determined that is safe and well tolerated by patients. will JNJ-90009530 help patients achieve a response and for how long?